Moderna is focusing on respiratory vaccines to sustain revenue streams amid COVID-19 declines. See more on MRNA stock and its ...

On Monday, Moderna Inc (MRNA) stock saw a decline, ending the day at $53.8 which represents a decrease of $-0.30 or -0.55% from the prior close of $54.1. The stock opened at $53.82 and touched a low ...

Based in Cambridge, Massachusetts, Moderna, Inc. (MRNA) is a leading biotechnology company that develops messenger RNA (mRNA) ...

In one of our recent articles about 10 High Growth Non-Tech Stocks That Are Profitable in 2024, we talked about how the US ...

Roivant's high valuation is justified, with a strong cash position, promising drug pipeline, and strategic partnerships ...

After hours: October 22 at 7:58 PM EDT ...

Looking at options history for Moderna MRNA we detected 21 trades. If we consider the specifics of each trade, it is accurate ...

The jab uses mRNA technology to tell the immune system to recognise a ‘foreign’ protein on viruses and mount an attack.

A first-of-its-kind study testing an mRNA vaccine for norovirus, the highly contagious winter vomiting bug, is launching in ...

A new FDA approval has given Pfizer a broader label for its respiratory syncytial virus (RSV) vaccine Abrysvo than rival ...

Experts hope the Moderna jab could stop people developing the vomiting and diarrhoea bug, which is linked to around 12,000 ...

Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the ...